Navigation Links
Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
Date:10/8/2008

Findings Confirm Potency of Poly-ICR as Vaccine Adjuvant

SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today presented positive data from preclinical studies using its proprietary Toll-like Receptor 3 agonist, Poly IC-Poly Arginine (Poly-ICR), at the World Vaccine Congress 2008 in Lyon, France. Study results demonstrated Poly-ICR to be a potent vaccine adjuvant targeting the Toll-like Receptor 3 (TLR3) pathway. Data showed that Poly-ICR, in combination with model antigens, elicits strong anti-target antibody and CD8 T-cell immune responses. These findings demonstrate the versatility of Poly-ICR, suggesting that the compound may possess broad potential for use in both therapeutic and prophylactic vaccines.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

Additional study findings presented today by Peter Emtage, Ph.D., Nventa's vice president of research and development, include:

-- Poly-ICR is stable and resistant to degradation by RNAses in

human serum;

-- Poly-ICR induces significant cytokine and chemokine production;

-- Poly-ICR matures dendritic cells, known as "the teachers of the

immune system".

In addition to incorporating Poly-ICR into future internal product candidates, Nventa is pursuing the development of Poly-ICR for topical application for the treatment of genital warts (GW) and actinic keratosis, a premalignant condition of the skin.

The company is also currently providing access to Poly-ICR to multiple leading vaccine developers in the U.S. and abroad, who are evaluating Poly-ICR for potential use into a wide range of vaccine products.

"These findings have confirmed the potency of Poly-ICR and highlighted the broad applicability of this compound for potential use in therapeutic and prophylactic vaccines," said
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Develops Proprietary Vaccine Adjuvant
2. Nventa to Present at Bio 2008 International Convention
3. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
7. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
8. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
9. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
10. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
11. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)...   Heska Corporation (NASDAQ: HSKA - ... advanced veterinary diagnostic and other specialty veterinary products , ... present at the 16th Annual B. Riley & Co. Investor ... conference will be held May 12-14, 2015 at Lowes Hollywood ... will be available during the day on May 13 for ...
(Date:5/1/2015)... , May 1, 2015 ... expanded its current therapeutic focus beyond addiction ... serious psychiatric disorders. Braeburn has acquired an ... second-generation) antipsychotic risperidone for treatment of schizophrenia ... Braeburn acquires global rights to other potential ...
(Date:5/1/2015)... May 1, 2015  Boston Scientific Corporation (NYSE: ... business momentum and long-term growth strategies at a meeting ... York City . President and Chief Executive Officer ... the company has to bring forward meaningful innovation to ... and deliver shareholder value. "We are ...
Breaking Medicine Technology:Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7
... NASHVILLE, Tenn., May 4, 2011 Cumberland Pharmaceuticals Inc. ... focused on hospital acute care and gastroenterology markets, today announced ...   For the three months ended March 31, 2011, net ... corresponding period in 2010. Revenue grew year-over-year despite a brief, ...
... May 4, 2011The U.S. Food and Drug Administration ... manufacture, market, or distribute over-the-counter (OTC) liquid drug ... to measure and dispense the doses of medication. ... The guidance, titled Dosage Delivery Devices for ...
Cached Medicine Technology:Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 10FDA Issues Final Guidance for Liquid OTC Drug Products With Dispensing Devices 2FDA Issues Final Guidance for Liquid OTC Drug Products With Dispensing Devices 3
(Date:5/3/2015)... May 03, 2015 “ BolehVPN ” was ... which features the latest and coolest technology products available to ... NewsWatch, conducted the review and shared with viewers how to ... does these days is on computers and even more so ... and meet people all over the world. In terms of ...
(Date:5/3/2015)... It is not too late to register to take part ... Lissa Anne Been in Arnold, Missouri on May 9, 2015. ... honor her loving memory. It has benefited the renowned Brain Aneurysm ... 37, Lissa suffered a brain aneurysm . After two operations ... event is designed to serve as a remembrance of her and ...
(Date:5/2/2015)... 02, 2015 Vancouver fencing company, QS Fencing, ... valuable advice to prospective clients related to their questions on ... install railings around their decks and patios. While that seems ... pop up once the person rolls up their sleeve to ... a railing in finding a gate that matches it. , ...
(Date:5/2/2015)... Delray Beach, FL (PRWEB) May 02, 2015 ... newspaper has selected The Delray Recovery Center as one ... Recovery Center is known in the addiction treatment field ... encourages staff members to innovate and to continue their ... promoting a positive workplace environment, never forgetting their purpose ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 As ... laxity issues of the face, neck and décolleté, ... concept with real potential for the success of ... the ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s Health ... FACS, ACGE, concluded that ThermiGyn’s temperature controlled radio ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... was first reported in the Luanda province of Angola on ... cholera// and 22 cholera related deaths have been reported in ... published by the World Health Organization, 101 new cholera and ... 24 hours. 8 municipalities have been reported to be affected ...
... children suffer from atopic eczema, a disease which causes the ... for new ways// to develop useful and powerful drug so ... eczema. ,Azathioprine is a drug that was developed ... their new organ. Its mechanism of action is by suppressing ...
... Nurses will now work for birth control in all the ... incidence of teenage pregnancies//. ,There are currently 2,409 nurses ... but the latest announcement signals a massive extension, reported the ... primary care trust will be funded to have at least ...
... new low nicotine Quest? cigarettes seems to have lulled ... a study conducted by researchers// at the Transdisciplinary Tobacco ... of Medicine.Results of the study have been published in ... author of this study, Caryn Lerman, PhD, Associate Director ...
... by the New England Research Institutes in collaboration with Yale ... too little// are at a greater risk of developing type ... on studies done on over 1709 men, in the age ... period of 15 yrs. ,According to the lead ...
... treatment of tuberculosis in the state would be achieved ... care sectors and NGOs, said health minister R Ashok, ... of the International TB day celebrations. ,The ... National Tuberculosis Control Programme (RNTCP) as being responsible for ...
Cached Medicine News:
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions....
KIMBERLY-CLARK BALLARD Neonatal and Pediatric TRACH CARE Manifold features lavage/irrigation port and locking thumb port. Multiple French sizes and packaging configurations. Gamma sterilized....
PVC. Low pressure cuff. X-ray opaque line. 15 mm Connector/swivel action. Obturator packed with sizes 6.0mm I.D - 10.5mm I.D. Single use....
Aire-Cuf® and Fome-Cuf® tracheostomy tubes with talk attachment are available in I.D. sizes from 5.0 mm to 9.5 mm. , ,Developed to aid the ventilator dependent patient in communicating with ...
Medicine Products: